AAVXF (Abivax) OCF Margin %: 0.00% (As of Mar. 2026)


AAVXF Abivax SA AAVXF
25 GF Score
Price $80.03
! 1 Warning Sign
View Full Analysis

What is Abivax OCF Margin %?

Abivax AAVXF -20.96% 25 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates AAVXF with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 960 Biotechnology companies, Abivax ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Abivax's Cash Flow from Operations for the three months ended in Mar. 2026 was $-58.40 Mil. Abivax's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Abivax's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Abivax's current OCF Yield % is -3.37%.

The historical rank and industry rank for Abivax's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Abivax was -12289.76%. The lowest was -84490.00%. And the median was -81127.78%.

AAVXF's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Abivax OCF Margin % Related Terms

Abivax OCF Margin % Historical Data

* Premium members only.

The historical data trend for Abivax's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax OCF Margin % Chart

Abivax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Abivax Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
AAVXF
25GF Score
Abivax SA AAVXF
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abivax OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Abivax's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-188.676/0
= %

Abivax's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-58.403/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Abivax (AAVXF) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Abivax and its competitors. According to the industry distribution chart, Abivax ranks #999999 out of 960 companies in the Biotechnology industry.
Is Abivax's OCF Margin % too high?
Abivax's current OCF Margin % is 0.00%. Based on the distribution chart, Abivax ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abivax has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Abivax's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abivax ranks #999999 out of 960 companies for OCF Margin %. This places Abivax in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Abivax and its competitors. Abivax's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abivax stock overvalued right now?
Abivax (AAVXF) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Abivax's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Abivax (AAVXF), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abivax Business Description

Address 7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
25GF Score

Get the complete analysis for AAVXF

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$80.03
Price